ADVENT Post Approval Study
← catalyst calendarNCT06431815 · readout ≤ 803 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
228actual
Sites
30
Countries
Brazil, Canada, Chile +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-25 | actual | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Atrial Fibrillation
Intervention
- Device: FARAPULSE™ Pulsed Field Ablation System — also filed as FARAWAVE™ Pulsed Field Ablation Catheter
Primary outcomes
what the primary-completion date above is the date OFComposite incidence of patients with procedure-related and device-related serious adverse events at 7-Days and 12-months post-Index Procedure.
measured 12 Months
Treatment success, defined as the incidence of subjects with successful isolation of clinically relevant pulmonary veins AND patients without recurrence or interventions for AF, AFL, AT after the blanking period through 12 months.
measured 12 Months
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed